The fifth place on the global sales list in 2019 was ibrutinib, which is a highly effective and selective small molecule BTK inhibitor for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma [13,14,15]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.